Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Net Margin (2018 - 2025)

Historic Net Margin for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 41.1%.

  • Exagen's Net Margin fell 9000.0% to 41.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.94%, marking a year-over-year increase of 3700.0%. This contributed to the annual value of 27.17% for FY2024, which is 179200.0% up from last year.
  • Per Exagen's latest filing, its Net Margin stood at 41.1% for Q3 2025, which was down 9000.0% from 25.81% recorded in Q2 2025.
  • Exagen's Net Margin's 5-year high stood at 19.69% during Q2 2024, with a 5-year trough of 192.87% in Q2 2022.
  • For the 5-year period, Exagen's Net Margin averaged around 56.64%, with its median value being 41.1% (2025).
  • In the last 5 years, Exagen's Net Margin crashed by -1426900bps in 2022 and then surged by 1574100bps in 2023.
  • Over the past 5 years, Exagen's Net Margin (Quarter) stood at 55.58% in 2021, then crashed by -112bps to 117.76% in 2022, then skyrocketed by 66bps to 40.25% in 2023, then skyrocketed by 32bps to 27.54% in 2024, then crashed by -49bps to 41.1% in 2025.
  • Its last three reported values are 41.1% in Q3 2025, 25.81% for Q2 2025, and 24.21% during Q1 2025.